The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma

To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients Clinical Trial

Official title:

The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04205201
• Other study ID #: CMC/PG/2018/1828
• Status: Completed
• Phase: Phase 2
• Start date: June 25, 2018
• Est. completion date: October 5, 2019

Study information

• Verified date: December 2019
• Source: Chittagong Medical College
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Outpatient department of cmch, ceitc,cimch POAG patients enrolled for the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: October 5, 2019
• Est. primary completion date: September 24, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• IOP 22_34mmof Hg,newly diagnosed case, bilateral POAG patients Patients.

Exclusion Criteria:

• pregnant and lactating women, infection, any eye surgery.

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients

Intervention

Drug:
• Drugs, Investigational
To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle

Locations

Country	Name	City	State
Bangladesh	Facuity of basic scienceand para clinican science	Chittagong	Chokhbazar
Bangladesh	Facuity of basic science and para clinical science	Dhaka	Chittagong

Sponsors (1)

Lead Sponsor	Collaborator
Chittagong Medical College

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	More than 20% IOP reduction	From baseline to month 3	0_3 months
Secondary	Adverse reaction	Record every follow up period baseline to month 3.	O_3 months